🇺🇸 FDA
Patent

US 11236340

Method of reducing the effects of aging-associated impairment of neurogenesis comprising modulating c-c chemokine receptor type 3 (CCR3)

granted A61KA61K2039/505A61K31/00

Quick answer

US patent 11236340 (Method of reducing the effects of aging-associated impairment of neurogenesis comprising modulating c-c chemokine receptor type 3 (CCR3)) held by United States Government as represented by the Department of Veterans Affairs expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
United States Government as represented by the Department of Veterans Affairs
Grant date
Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K2039/505, A61K31/00, A61K31/7088, A61K38/19